Biomarker Data From the Phase III KATHERINE Study of Adjuvant T-DM1 Versus Trastuzumab for Residual Invasive Disease After Neoadjuvant Therapy for HER2-Positive Breast Cancer.

Carsten Denkert Chiara Lambertini Peter Andreas Fasching Katherine L Pogue-Geile Max Senna Mano Michael Untch Norman Wolmark Chiun-Sheng Huang Sibylle Loibl Eleftherios P P Mamounas Charles E Geyer Peter C Lucas Thomas Boulet Chunyan Song Gail D Lewis Phillips Malgorzata Nowicka Sanne de Haas Mark Basik

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

T-DM1 appears to overcome HER2 resistance. T-DM1 benefit does not appear dependent on immune activation, but these results do not rule out an influence of the tumor immune microenvironment on degree of response.

Keyphrases

phase iii
positive breast cancer
open label
clinical trial
glycemic control
stem cells
rectal cancer
early stage
phase ii
electronic health record
locally advanced
epidermal growth factor receptor
squamous cell carcinoma
radiation therapy
study protocol
deep learning